bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events
Item 8.01 Other Events
On May 2, 2017, bluebird bio, Inc. (bluebird) issued two press
releases announcing that it has entered into separate worldwide
license agreements with respect to its proprietary lentiviral
vector platform.
The full text of the press releases are filed as Exhibits 99.1
and 99.2 to this Current Report on Form 8-K and are incorporated
herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press release issued by bluebird bio, Inc. on May 2, |
|
99.2 |
Press release issued by bluebird bio, Inc. on May 2, |
ACTIVE/71742392.1
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline. bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information
bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session up +1.65 at 90.60 with 280,121 shares trading hands.
